Ofloxacin solution for persistent exit-site and tunnel infection in peritoneal dialysis.
S Q
SQ
Lew
A
A
Gruia
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D055499:Catheter-Related Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D002408:Catheters, Indwelling / Q000382:microbiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000302:isolation & purification; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D015242:Ofloxacin